Azura Ophthalmics Limited Alternatives & Competitors

12 companies similar to Azura Ophthalmics Limited — Delivering First-in-Class Ophthalmic Keratolytics.

Dermavant Sciences, an Organon company

A Passion for Science and a Commitment to Dermatology

161 Private Equity $160.00M

Long Beach, United States

Biotechnology Health Care

Ascendis Pharma

Committed to making a meaningful difference for patients

1046 Post-IPO Debt $1.42B

Denmark

Biotechnology Health Care

Ultragenyx

Going Beyond Every Day

1535 Post-IPO Equity $1.14B

Novato, United States

Biotechnology Health Care +1

CV6 Therapeutics, (NI) Ltd.

CV6 Therapeutics is dedicated to improving patients lives through the development of novel...

11 Venture round $8.00M

United Kingdom

Biotechnology Health Care +1

Track all Azura Ophthalmics Limited competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Sudo Biosciences

Developing precision TYK2 therapeutics.

27 Series B $67.00M

Carmel, United States

Biopharma Biotechnology +2

Angitia Biopharmaceuticals

Developing innovative medicines to address serious musculoskeletal diseases

52 Series B $156.00M

Westlake Village, United...

Biopharma Biotechnology +1

Dualyx

Discovery and development of highly innovative biologicals for the treatment of autoimmune...

6 Series A $40.00M

Belgium

Biotechnology Health Care

Gemini Therapeutics

Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovat...

Post-IPO Equity $139.50M

Biopharma Biotechnology +1

Olympic Ophthalmics

Solving a large unmet need in eye-care with a drug-free home-health solution

3 Series A

Issaquah, United States

Biotechnology Health Care +2

IXALTIS SA

DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS

2 Venture round $8.00M

Toulouse, France

Biopharma Biotechnology +4

Handl Therapeutics

Handl Therapeutics develops gene therapies for complex neurodegenerative diseases through...

Grant $3.00M

Leuven, Belgium

Biotechnology Health Care +1

Tavotek Biotherapeutics

Innovative Therapies. Better Health.

8 Series B $55.00M

United States

Biopharma Biotechnology +2

About Azura Ophthalmics Limited

Azura Ophthalmics Limited is a biotechnology and healthcare startup based in Israel, founded in 2014. The company's slogan - "Delivering First-in-Class Ophthalmic Keratolytics" - reflects its focus on addressing underserved ophthalmic conditions. Azura Ophthalmics is leveraging its deep understanding of ocular surface...

Taxonomy

Ophthalmic Keratolytics, Ocular Surface Diseases, Drug Development, Therapeutic Class, Ophthalmologic Solutions, Dermatologic Solutions, Keratolytics, Underserved Ophthalmic Conditions, Pipeline Development, Chemical Entities, First-in-Class Therapeutics, Unmet Needs

Frequently Asked Questions

Companies similar to Azura Ophthalmics Limited include Dermavant Sciences, an Organon company, Ascendis Pharma, Ultragenyx, CV6 Therapeutics, (NI) Ltd., Sudo Biosciences. They work in Biotechnology and Health Care and share Azura Ophthalmics Limited's focus on drug development, pipeline development and first-in-class therapeutics.

Bounce Watch lists 12 companies that share Azura Ophthalmics Limited's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches Azura Ophthalmics Limited and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

Azura Ophthalmics Limited Profile Dermavant Sciences, an Organon company Alternatives Ultragenyx Alternatives CV6 Therapeutics, (NI) Ltd. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Azura Ophthalmics Limited on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.